Millennium entities report 5.2% iBio (IBIO) ownership in Schedule 13G

Rhea-AI Filing Summary

iBio, Inc. received a Schedule 13G filing from several Millennium-affiliated investment entities and Israel A. Englander disclosing a new passive ownership position. Integrated Core Strategies (US) LLC reports beneficial ownership of 1,234,295 shares of iBio common stock, while Millennium Management LLC, Millennium Group Management LLC and Mr. Englander each report 1,235,827 shares, representing 5.2% of the outstanding common stock in each case.

The ownership percentage is based on 23,895,789 iBio shares outstanding, combining 22,487,308 shares reported in a prior Form 10‑Q/A and 1,408,481 shares issued in a recent private placement. The reporting persons certify the shares were not acquired and are not held for the purpose of changing or influencing control of iBio, and they entered into a joint filing agreement to report this position together.

Insights

Institutional ownership analyst

Millennium-linked funds disclose a passive 5.2% stake in iBio.

The filing shows Integrated Core Strategies (US) LLC and other Millennium-affiliated entities, including Millennium Management LLC and Israel A. Englander, collectively reporting beneficial ownership of about 1.23M iBio common shares. Each reporting person cites 5.2% of the outstanding class, using a base of 23,895,789 shares that includes stock from a recent private placement.

The disclosure is on a Schedule 13G, which is used for passive ownership, and the signatories explicitly certify the position was not acquired to change or influence control of iBio. Voting and investment power is reported as shared rather than sole, reflecting that the securities are held through entities under Millennium’s management structure.

The filing also references a joint filing agreement dated January 21, 2026, confirming coordinated reporting among the listed entities. Future ownership levels and any shift from passive to active intent, if they occur, would typically appear in subsequent beneficial ownership filings.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

iBio, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

451033708

(CUSIP Number)

01/15/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 451033708

1

Names of Reporting Persons

Integrated Core Strategies (US) LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,234,295.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,234,295.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,234,295.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 451033708

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,235,827.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,235,827.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,235,827.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 451033708

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,235,827.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,235,827.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,235,827.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 451033708

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,235,827.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,235,827.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,235,827.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: iBio, Inc.
(b)	Address of issuer's principal executive offices: 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121
Item 2.
(a)	Name of person filing: Integrated Core Strategies (US) LLC Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Integrated Core Strategies (US) LLC c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Integrated Core Strategies (US) LLC - Delaware Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 451033708
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page.
(b)	Percent of class: See response to Item 11 on each cover page. The percent of class was calculated based on 23,895,789 shares of Common Stock outstanding, which is the sum of (i) 22,487,308 shares of Common Stock outstanding as of November 10, 2025, as reported in the Issuer's Form 10-Q/A filed with the SEC on November 17, 2025, and (ii) 1,408,481 shares of Common Stock issued in connection with a private placement that closed on or about January 13, 2026, as reported in the Issuer's Form 8-K filed with the SEC on January 12, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit I
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Integrated Core Strategies (US) LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	01/21/2026

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	01/21/2026

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	01/21/2026

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	01/21/2026

Comments accompanying signature: ** INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of January 21, 2026, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

FAQ

What ownership stake in iBio (IBIO) did Millennium-affiliated entities disclose?

They reported beneficial ownership of approximately 1,235,827 shares of iBio common stock, representing 5.2% of the outstanding shares for each of Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander, and 1,234,295 shares (also 5.2%) for Integrated Core Strategies (US) LLC.

Is the Millennium stake in iBio (IBIO) reported as passive or active?

The position is reported on a Schedule 13G, and the signatories certify that the securities were not acquired and are not held for the purpose of changing or influencing control of iBio.

How was the 5.2% ownership in iBio (IBIO) calculated?

The 5.2% figure is based on 23,895,789 iBio common shares outstanding, which combines 22,487,308 shares from a Form 10‑Q/A and 1,408,481 shares issued in a private placement reported in a Form 8‑K.

Who are the reporting persons in the iBio (IBIO) Schedule 13G?

The reporting persons are Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, all listing U.S. or Delaware as their jurisdiction of organization or citizenship.

What voting and dispositive powers do the reporting persons have over iBio (IBIO) shares?

Each reporting person lists 0 shares with sole voting or dispositive power and between 1,234,295 and 1,235,827 shares with shared voting and shared dispositive power, as shown on their respective cover pages.

Is there a joint filing agreement related to this iBio (IBIO) Schedule 13G?

Yes. Exhibit I is a Joint Filing Agreement dated January 21, 2026, among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.